Stockscreener 앱 받기
9.08
8.19%
-0.81
시장 영업 전:
9.08
전일 마감가:
$9.89
열려 있는:
$10
하루 거래량:
1.15M
Relative Volume:
1.04
시가총액:
$484.43M
수익:
$1.02B
순이익/손실:
$-757.20M
주가수익비율:
-0.6152
EPS:
-14.76
순현금흐름:
$-257.90M
1주 성능:
-12.02%
1개월 성능:
-7.63%
6개월 성능:
+30.84%
1년 성능:
+2.25%
1일 변동 폭
$9.07
$10.21
1주일 범위
$9.07
$10.39
52주 변동 폭
$4.02
$13.41
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
EBS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
9.08 | 519.42M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Is Emergent BioSolutions Inc. stock undervalued at current price2025 Historical Comparison & AI Enhanced Trading Signals - newser.com
Why Emergent BioSolutions Inc. stock could outperform in 20252025 Trading Volume Trends & Precise Trade Entry Recommendations - newser.com
Is Emergent BioSolutions Inc. stock undervalued historicallyJuly 2025 News Drivers & Consistent Growth Stock Picks - newser.com
Why Emergent BioSolutions Inc. (ER4) stock is trending on social media2025 Institutional Moves & High Yield Stock Recommendations - newser.com
Will Emergent BioSolutions Inc. stock deliver consistent dividends2025 Earnings Surprises & Safe Swing Trade Setup Alerts - newser.com
Can Emergent BioSolutions Inc. stock deliver consistent EPS growth2025 Volume Leaders & Verified Entry Point Signals - newser.com
Will Emergent BioSolutions Inc. stock gain from green policiesJuly 2025 Opening Moves & Scalable Portfolio Growth Ideas - newser.com
How Emergent BioSolutions Inc. stock compares with tech leadersPortfolio Update Summary & Entry Point Strategy Guides - newser.com
How dovish Fed policy supports Emergent BioSolutions Inc. stockJuly 2025 Market Mood & High Accuracy Trade Signal Alerts - newser.com
Why millennials buy Emergent BioSolutions Inc. (ER4) stockPrice Action & AI Driven Stock Movement Reports - newser.com
Is Emergent BioSolutions Inc. stock resilient in recession scenariosPortfolio Gains Report & Daily Technical Forecast Reports - newser.com
Visual analytics tools that track Emergent BioSolutions Inc. performanceWeekly Investment Recap & Daily Stock Momentum Reports - newser.com
What makes Emergent BioSolutions Inc. stock appealing to growth investorsEarnings Overview Report & AI Powered Trade Plan Recommendations - newser.com
Understanding Emergent BioSolutions Inc.’s price movement2025 Major Catalysts & Weekly Sector Rotation Insights - newser.com
Published on: 2025-11-19 05:25:17 - newser.com
Published on: 2025-11-19 04:54:10 - newser.com
Chart based exit strategy for Emergent BioSolutions Inc.2025 Biggest Moves & Community Consensus Picks - newser.com
Reversal indicators forming on Emergent BioSolutions Inc. stockDay Trade & Daily Technical Stock Forecast Reports - newser.com
What technical patterns form on Emergent BioSolutions Inc. (ER4) stock charts - newser.com
Editor: 【Capital Growth】 - newser.com
Emergent’s NARCAN nasal spray marks 10 years since FDA approval By Investing.com - Investing.com Nigeria
Emergent’s NARCAN nasal spray marks 10 years since FDA approval - Investing.com India
Emergent BioSolutions marks 10-year anniversary of the U.S. FDA approval of Narcan nasal spray and reinforces its commitment to increasing naloxone access - MarketScreener
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access - The Manila Times
Emergent BioSolutions (NYSE: EBS) marks 10 years of NARCAN, 85M doses used - Stock Titan
Analyzing Emergent BioSolutions Inc. with multi timeframe chartsJuly 2025 Big Picture & Growth Focused Stock Reports - newser.com
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.17%
0.67%
자본화:
|
볼륨(24시간):